Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Janssen

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

The Conversation

Supply of medicines to NZ threatened after vaccine disclosure – Ombudsman

After the Government mistakenly released confidential information about Covid-19 vaccines, the health ministry says it was 'made clear' this could have implications for broader pharmaceutical and therapeutic supply.

Newsroom.co.nz

From analysis to the latest developments in health,
read the most diverse news in one place.

Mark Cuban Has Good News for People with Diabetes

The billionaire's online pharmacy will offer one of the most expensive treatments for type 2 diabetes at half the price.

The Street

Billionaire Mark Cuban Is Pulling Off His Biggest Bet

The billionaire's online pharmacy will offer one of the most expensive treatments for type 2 diabetes at half the price.

The Street

Mark Cuban Scores Huge Win in Fight to Disrupt Big Pharma

The billionaire's online pharmacy will offer one of the most expensive treatments for type 2 diabetes at half the price.

The Street

J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out

Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Monkeypox: latest data reveals how the virus has affected women and non-binary people

Since May 2022, a global outbreak of human monkeypox infections has been reported in over 78,000 people. So far, infections have overwhelmingly occurred in sexually active men who have sex with men.

The Conversation

Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.

Benzinga

Why Did HC Wainwright Downgrade Addex Therapeutics

Last week, Addex Therapeutics Ltd (NASDAQ:ADXN) terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow rate of patient recruitment. Addex is suspending its financial guidance. Hence HC Wainwright downgraded its rating to Neutral from Buy without a price target, as dipraglurant…

Benzinga

F-star Therapeutics Shares Are Rallying Today - Read Why

invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ:FSTX) for $7.12 per share. The proposed acquisition values F-star at approximately $161 million. Just a year ago, F-star priced its IPO at $7. F-star's next-generation tetravalent (2+2) bispecific antibody platform complements Sino Biopharma's existing capabilities and reinforces its global…

Benzinga

Legend Biotech Shares Move Higher After Bullish BMO Pitch

BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ:LEGN) with a price target of $77, and an Outperform rating. The analyst says the company's recently approved Carvykti for multiple myeloma is best-in-class late-line CAR T therapy. Related: EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy Though the analyst expects a gradual increase in sales due…

Benzinga

Addex Stops Parkinson's-Associated Dyskinesia Trial - Read Here Why

Addex Therapeutics Ltd (NASDAQ:ADXN) has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients. Data readout from the trial was expected in 1H of 2023. The company attributes this to the consequences of COVID-19-related patient concerns about participation in studies, staffing…

Benzinga

5 Durable Stocks to Strengthen Your Portfolio

Given the current market turmoil caused due to surging inflation and the Fed’s aggressive interest rate hikes to bring prices down, it could be wise to invest in stocks that do not fluctuate significantly in adverse market conditions. The solid stability of Johnson & Johnson (JNJ), Coca-Cola FEMSA (KOF), Marubeni…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug

Immix Biopharma Inc (NASDAQ:IMMX) announced positive interim data from an animal study in Soft Tissue Sarcoma (STS). STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for…

WEKU

FDA limits Johnson & Johnson's COVID vaccine to some people due to blood clot risk

The chances of dying following after receiving the Janssen vaccine is about 1:2,000,000. But with multiple COVID-19 vaccines available, the FDA is limiting the use of the J&J vaccine.

Wales Online

Covid booster gives long-lasting protection, study finds

'The longer-term protection against hospitalisation and death is perhaps the most important factor for future booster programmes'

The Independent UK

Third Covid-19 vaccine dose offers ‘prolonged immune response’ – UK-wide study

The study compared immune responses to seven vaccines used as a booster 28 days after two initial doses.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen

Alkermes plc (NASDAQ:ALKS) commenced binding arbitration proceedings regarding two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson (NYSE:JNJ). Under these agreements, Janssen received access and rights to Alkermes' small particle pharmaceutical compound technology, known as NanoCrystal Technology, enabling several products. Janssen partially terminated the agreements in the U.S., effective as of…

The Independent UK

J&J's Janssen settles with WVa for $99M in opioid lawsuit

West Virginia will receive $99 million in a settlement finalized with Johnson & Johnson’s subsidiary Janssen Pharmaceuticals Inc. The state filed a lawsuit accusing the drugmaker of contributing to the opioid crisis in the state that's led the nation in overdose deaths

Benzinga

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

Johnson & Johnson's (NYSE:JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ:GMAB) on two matters related to their licensing pact for multiple myeloma drug Darzalex (daratumumab). The first issue around daratumumab arose because Janssen announced a deal with Halozyme Therapeutics Inc (NASDAQ: HALO) to develop a subcutaneous formulation of daratumumab. According to Janssen, Genmab must share…

Benzinga

EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy

The European Medicines Agency's CHMP

Benzinga

Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech

Protagonist Therapeutics (NASDAQ:PTGX) has received a $25 million milestone payment from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ). The payment comes after the dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113). FRONTIER 1 is a Phase 2b dose-ranging study to evaluate the…

Benzinga

AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial

AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a

Benzinga

Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced a

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.